This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

KEYTRUDA® (pembrolizumab) in adjuvant melanoma monotherapy treatment diary

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

This downloadable diary has been designed for HCPs like yourself, to provide your patients already on/or recently prescribed KEYTRUDA monotherapy for the adjuvant treatment of melanoma.

This diary contains information about KEYTRUDA monotherapy, including its method of administration, mode of action, possible side effects and what the patient should do if they notice any signs or symptoms. It is also designed to support your consultations with a patient by providing space to record any questions they may have as well as their future appointment dates, and also to help support patients to monitor adverse events and safety related issues.

Please be aware you should not direct your patient to this website. You should download this diary on their behalf and share it with them as appropriate.

More information about KEYTRUDA® (pembrolizumab) in melanoma

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-OOC-00380 | Date of Preparation: October 2021